Close Menu

NEW YORK – Biocept reported after the close of the market on Thursday that its third quarter revenues more than quadrupled year over year driven by its current offering of molecular COVID-19 testing services.

For the three months ended Sept. 30, the San Diego-based liquid biopsy company posted $6.6 million in revenues compared to $1.5 million in Q3 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.